Additionally, PAK1 inhibition is plausible for cancers in which PAK1 converges crucial signaling transductions of aberrated oncogenes (e.g, ErbB2, TRIO) or tumor suppressor genes (e,g NF1) 13, 34, 35. This evidence concerns the gene ERBB2 and cancer.